24,604 Shares in Novo Nordisk A/S $NVO Purchased by Runnymede Capital Advisors Inc.

Runnymede Capital Advisors Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 24,604 shares of the company’s stock, valued at approximately $1,252,000.

Other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC increased its position in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $25,000. American National Bank & Trust purchased a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $28,000. Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $30,000. Finally, Allianz SE increased its position in shares of Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi‑month subscription program for Wegovy to lower out‑of‑pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self‑pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross‑trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP‑1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug‑pricing body for heart‑disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium‑term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once‑a‑week insulin work and early triple‑agonist studies — supports longer‑term growth optionality beyond current GLP‑1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP‑1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low‑cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re‑pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near‑term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of research reports. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $36.92 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The business has a 50 day moving average price of $43.43 and a two-hundred day moving average price of $49.74. The firm has a market cap of $164.86 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 50.43%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.